Eli Lilly Files Five New Retatrutide Lawsuits, Total Active Cases at Nine
Eli Lilly filed five new federal suits against unapproved retatrutide sellers on October 8, bringing its total to 11 since August with nine currently active.
Category Industry
DOJ Charges Two Indian Nationals in Counterfeit Ozempic Scheme
A federal grand jury in Florida charged two Indian nationals with smuggling counterfeit Ozempic sourced from China into U.S. distribution channels.
Lilly, FDA Clash in Seventh Circuit Over Retatrutide Classification
Oral arguments September 24 will determine whether retatrutide gets 12 or 5 years of data exclusivity, with major implications for the obesity drug pipeline.
Fifth Circuit Affirms FDA GLP-1 Delisting, Restricts Compounding
The Fifth Circuit upheld FDA's removal of semaglutide and tirzepatide from the shortage list, closing a key legal pathway for compounded GLP-1 production.
Seventh Circuit Sets Sept. 24 Arguments in Retatrutide Biologics Case
The Seventh Circuit will hear oral arguments September 24 in Eli Lilly v. RFK Jr., a case that could determine whether retatrutide is classified as a biologic or conventional drug.
Lawsuits in Three States Allege Compounded GLP-1s Caused Medical Emergencies
Three patients in three states report serious medical emergencies tied to compounded GLP-1 medications, raising questions about telehealth prescribing and compounding quality control.
Fox News Opinion Piece Flags China-to-US Retatrutide Pipeline
A Fox News opinion essay describes retatrutide, an investigational drug in Phase 3 trials, being shipped from China into US homes via gray-market channels.
FDA Approves Mounjaro to Cut CV Risk in Type 2 Diabetes
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high risk, based on SURPASS-CVOT trial results.
Qatar MOPH Bans Handling of Unlicensed Peptide Products
Qatar's MOPH issued Circular PDC/2026/31 prohibiting handling, distribution, use, and promotion of unlicensed peptide products, effective immediately.
NBC News Finds No National System Tracks Peptide Adverse Events
NBC News finds the U.S. lacks a comprehensive system for tracking peptide adverse events, leaving safety gaps beyond approved GLP-1 drugs.
